cagrilintide fda Novo Nordisk Submits CagriSema for FDA Approval for Obesity Treatment Cagrilintide - PeakForm Peptides

This product is not classified as a drug or supplement

Cagrilintide is a long-acting analog of amylin (islet amyloid polypeptide), a pancreatic hormone co-secreted with insulin that induces satiety

tirzepatide activates the GIP and GLP-1 incretin receptors and adds a glucose-dependent insulin-secretion effect that an amylin analog does not have

The pattern is consistent: wherever there is an approved, completed human RCT in this pair, it belongs to tirzepatide

[2] The Phase 3a REDEFINE 2 trial then tested once-weekly CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) against placebo in 1,206 adults with obesity and type 2 diabetes over 68 weeks, reporting a mean bodyweight change of 13.7% versus 3.4% for placebo

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations